Search results
Exelixis' XL092/ Atezolizumab Shows Encouraging Efficacy, Safety In Heavily Pretreated Cancer...
Benzinga via Yahoo Finance· 2 years agoExelixis Inc (NASDAQ: EXEL) announced results from the dose-escalation stage of STELLAR-001, an...
England to rollout world-first seven-minute cancer treatment jab
Reuters via Yahoo News· 10 months agoFollowing approval from the Medicines and Healthcare products Regulatory Agency (MHRA), NHS England...
Exelixis (EXEL) Begins Study on XL092 Combo in Colorectal Cancer
Zacks via Yahoo Finance· 2 years agoExelixis (EXEL) starts the phase III STELLAR-303 study evaluating XL092 in combination with...
Phanes Therapeutics signs clinical supply agreement with Roche
Clinical Trials Arena via Yahoo Finance· 1 month agoUS-based biopharmaceutical company Phanes Therapeutics has announced a clinical supply agreement...
Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo
Benzinga via Yahoo Finance· 1 year agoExelixis Inc (NASDAQ: EXEL) announced that the phase 3 CONTACT-03 study did not meet its primary...
Affimed N.V. (NASDAQ:AFMD) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 day agoAffimed N.V. (NASDAQ:AFMD) Q1 2024 Earnings Call Transcript June 12, 2024 Affimed N.V. beats...
Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More
Zacks via Yahoo Finance· 1 year agoThe biotech sector was in focus with key pipeline and regulatory updates. Among these, BMRN was down...
Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More
Zacks via Yahoo Finance· 10 months agoIt was a low-key week for the biotech sector as the earnings season ended and nothing much came from...
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
Benzinga via Yahoo Finance· 2 years agoExelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study did not meet its primary endpoint of...
Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint
Zacks via Yahoo Finance· 10 months agoExelixis, Inc. EXEL and partner Ipsen announced that the late-stage CONTACT-02 study achieved one of...